Dose-Finding Study of Fluoxetine and Venlafaxine for the Treatment of Self-Injurious and Stereotypic Behavior in Rhesus Macaques (Macaca mulatta)

M Babette Fontenot,1,2 Mandi W Musso,1 Robert M McFatter,3 and George M Anderson3

The short-term effects on rates and durations of self-injurious behavior and self-directed stereotypies associated with various doses of fluoxetine (FLX) and venlafaxine (VEN) were examined in rhesus macaques. Adult male macaques (Macaca mulatta; n = 17; age, 7 to 15 y) with at least 1 episode of severe SIB within the past 5 y were randomized to treatment with FLX (n = 6), VEN (n = 6), or placebo (PLC, n = 5), administered by voluntary consumption of medication provided in fruit-flavored tablets. After 4-wk baseline and 4-wk placebo lead-in phases, doses were increased monthly for 4 mo (FLX: 0.5, 2.0, 4.0, and 8.0 mg/kg; VEN: 2.0, 4.0, 8.0, and 16.0 mg/kg). Animals in the PLC condition received similar nonmedicated fruit-flavored tablets. Focal behavioral observations, plasma drug levels, and neurochemical data were obtained. Results indicated that rates and percentage time spent self-biting declined at all doses of FLX, with the greatest effect seen at 2.0 mg/kg. For VEN, percentage time spent self-biting was significantly lower only at the 4.0 mg/kg dose. Treatment-induced reductions in platelet serotonin and cerebrospinal fluid 5-hydroxyindoleacetic acid (CSF 5HIAA) concentrations were substantially greater in the FLX-treated condition than in the VEN-treated condition. Plasma FLX and norfluoxetine levels increased with FLX dose; plasma levels of VEN were low and not dose-related. Fluoxetine at a dose of 2.0 mg/kg daily was most efficacious in reducing SIB, and the observed reductions in platelet serotonin and CSF 5HIAA levels indicated substantial bioeffect at this dose. Treatment with VEN was marked by noncompliance, low bioeffect, and low efficacy.

Abbreviations: bpm, beats per minute; CSF 5HIAA, cerebrospinal fluid 5-hydroxyindoleacetic acid; FLX, fluoxetine; PLC, placebo; SIB, self-injurious behavior; SNRI, serotonin–norepinephrine reuptake inhibitor; VEN, venlafaxine.

Self-injurious behavior (SIB) is a considerable problem in adult rhesus macaques socially deprived in infancy or individually housed in captivity.1,4,14-20,33-35,41,42,50,51 In 1 report,30 the incidence of self-injury was estimated to be as high as 14% in captive populations of rhesus monkeys, the vast majority of which are male, with self-biting being the most prevalent form of injury. In a survey of 362 individually housed rhesus monkeys (age, 2 to 21 y) that had been housed individually for 4.6 ± 0.18 y (mean ± SE),34 33.7% exhibited self-directed stereotypic behavior and 25% exhibited self-biting behavior. Self-directed stereotypic behavior was positively correlated with age. Animals with severe SIB (mean, 9.8 y) were significantly older than those without a history of wounding (mean, 7.0 y). Although self-wounding can be an infrequent event, self-biting in this severe SIB population occurs frequently throughout the day in approximately 78% of animals.30 Severe cases of self-biting require prolonged veterinary care and often result in the removal of animals from research protocols.

Current research has focused on identifying the etiology of SIB with the ultimate goal of prevention. Some monkeys have an increased vulnerability that is associated with stressful social experiences in the first 2 y of life, such as early weaning. In susceptible adult animals, the behavior may be triggered by separation from sexual partners or social groups,8,17 contact with fear-provoking personnel,45 or disruption of daily routines.30 In 1 study,19 outdoor housing resulted in decreases in SIB and self-directed stereotypic behavior among animals previously housed indoors. However, among indoor-housed animals, manipulation of the environment by increasing cage space29,31 or providing toys,39 puzzle-feeders,41 or forage boards32 appears to have little effect on SIB. The limited utility of environmentally based interventions suggests that pharmacologic treatment of SIB should be examined carefully.

Previous studies suggest that serotonergic compounds are useful for short-term treatment of SIB and self-directed stereotypic behavior in macaques18 and for treatment of compulsive behaviors in companion animal species.27 Selective serotonin reuptake inhibitors, such as fluoxetine (FLX) and sertraline, have efficacy in the treatment of acral lick dermatitis in dogs.44,52 The tricyclic antidepressant clomipramine has been used effectively to treat compulsive behavior in cats19 and dogs.10,22 To date, no studies have examined the effects of combined serotonin–norepinephrine reuptake inhibitors on anxiety or compulsive behaviors in companion animals. However, the serotonin–norepinephrine reuptake inhibitor (SNRI) venlafaxine (VEN) appears to offer a profile similar to clomipramine with decreased side effects and has efficacy in the treatment of depression, panic attacks, and obsessive–compulsive behavior in humans.11-13,26,38
We performed a dose-finding study to establish optimal doses of subchronic FLX and VEN for the treatment of SIB and stereotypic behavior in adult male rhesus macaques. Rates and durations of SIB and self-directed stereotypies and plasma drug levels associated with escalating doses of FLX and VEN were quantified. In addition, the effects of FLX and VEN on platelet serotonin (5-hydroxytryptamine) and cerebrospinal fluid levels of the serotonin metabolite 5-hydroxyindoleacetic acid (5HIAA) were measured to assess the bioeffect of the agents.

**Materials and Methods**

**Animals.** The study included 17 male Indian-origin rhesus macaques (*Macaca mulatta*; age, 7 to 15 y). All animals were screened for evidence of self-wounding and characterization of self-directed stereotypic behavior. To be included in the study, an animal had to be singly housed and have had at least 1 episode of severe SIB requiring veterinary intervention within the past 5 y. In addition, subjects were not treated with any medication specifically for SIB for at least 1 y prior to this study (Table 1).

Animals were inspected twice daily, in the morning and afternoon, for the presence of wounds. Incidents of new injuries (that is, punctures and lacerations) were recorded daily. An incident was classified as the presence of any new punctures or lacerations that day.

The animals were housed individually in 0.56 m² cages in a 1-tiered system and fed a commercially available primate chow twice daily. Water was provided *ad libitum*. Additional fresh fruit and foraging devices were provided at least 5 d each week for enrichment. All animals were provided with manipulanda, including commercially available toys and wood, in accordance with the University of Louisiana at Lafayette–New Iberia Research Center plan for Environmental Enhancement and Behavioral Management. Husbandry was performed daily between 07:30 to 08:30.

The animals were serologically negative for simian retrovirus, simian T-cell leukemia virus, simian immunodeficiency virus, and B virus (*Cercopithecine herpesvirus 1*). All experimental procedures were approved by the Institutional Animal Care and Use Committee.

**Dose selection.** Doses were selected based on allometric scaling from therapeutic dosages in humans (average weight, 70 kg):46

\[
\text{Dosage (mg/kg)}_{\text{macaque}} = \text{dosage (mg/kg)}_{\text{human}} \times \left(\frac{\text{body weight}_{\text{human}}}{\text{body weight}_{\text{macaque}}}\right)^{0.25}
\]

Significant protein binding, capacity-limited biotransformation, and genetic polymorphisms of cytochrome P<sub>450</sub> isoenzymes all may influence the application of this equation. However, extrapolation from therapeutic ranges in humans provides all may influence the application of this equation. However, extrapolation from therapeutic ranges in humans provides an estimate for dosages in macaques.46 The dose extrapolation from therapeutic ranges in humans (average weight, 70 kg):46

\[
\text{Dosage (mg/kg)}_{\text{human}} = \text{dosage (mg/kg)}_{\text{macaque}} \times \left(\frac{\text{body weight}_{\text{macaque}}}{\text{body weight}_{\text{human}}}\right)^{0.25}
\]

**Randomization and dosing schedule.** Animals were randomly assigned to 1 of 3 treatment conditions: FLX (n = 6), VEN (n = 6), and placebo (PLC; n = 5). After a 4-wk baseline period (B), a 4-wk lead-in placebo period (PF) was initiated. The animals then received, at 4-wk intervals, increasing doses of FLX (0.5, 2.0, 4.0, and 8.0 mg/kg daily) or VEN (2.0, 4.0, 8.0, and 16.0 mg/kg daily) (Figure 1). All medication was administered orally in a commercially prepared fruit-flavored scored tablet (Bioserv, Frenchtown, NJ). Tablets were available in 20 mg or 40 mg formulations. Animals in the PLC condition received nonmedicated fruit-flavored tablets. Animals were dosed daily between 10:00 to 12:30. Animals that did not consume the medicated tablets were offered medication in food or fruit treats. Not all animals consumed 100% of the medication daily; therefore, percentage consumption was recorded as the amount of the medicated food treat or tablet consumed.

**Plasma drug and metabolite concentrations.** Trough plasma levels of FLX, norfluoxetine, and VEN were determined from early-morning blood samples obtained before the daily dose of drug (Figure 1). Fluoxetine and norfluoxetine levels in plasma were assayed by using a method that we have previously used to measure the compounds in human plasma46 and were determined with within-assay coefficients of variation of 4% and 6%, respectively, and assay-to-assay coefficients of variation of 8 and 11%, respectively. Plasma VEN concentration was measured by using a similar HPLC–UV absorbance method.

### Table 1. Subject history: age, incidence of severe SIB, and weight

<table>
<thead>
<tr>
<th>Animal</th>
<th>Treatment</th>
<th>Age (y)&lt;sup&gt;a&lt;/sup&gt;</th>
<th>No. months single-housed</th>
<th>No. of incidents of severe SIB during last 5 y&lt;sup&gt;b&lt;/sup&gt;</th>
<th>No. months since last SIB incident&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Weight (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>FLX</td>
<td>7</td>
<td>61</td>
<td>5</td>
<td>7</td>
<td>10.70</td>
</tr>
<tr>
<td>B</td>
<td>FLX</td>
<td>7</td>
<td>84</td>
<td>3</td>
<td>13</td>
<td>12.60</td>
</tr>
<tr>
<td>C</td>
<td>FLX</td>
<td>8</td>
<td>73</td>
<td>3</td>
<td>11</td>
<td>11.25</td>
</tr>
<tr>
<td>D</td>
<td>FLX</td>
<td>9</td>
<td>64</td>
<td>3</td>
<td>44</td>
<td>10.80</td>
</tr>
<tr>
<td>E</td>
<td>FLX</td>
<td>9</td>
<td>83</td>
<td>9</td>
<td>31</td>
<td>11.90</td>
</tr>
<tr>
<td>F</td>
<td>PLC</td>
<td>10</td>
<td>102</td>
<td>4</td>
<td>27</td>
<td>10.60</td>
</tr>
<tr>
<td>G</td>
<td>PLC</td>
<td>7</td>
<td>69</td>
<td>2</td>
<td>6</td>
<td>9.60</td>
</tr>
<tr>
<td>H</td>
<td>PLC</td>
<td>9</td>
<td>73</td>
<td>5</td>
<td>15</td>
<td>13.75</td>
</tr>
<tr>
<td>I</td>
<td>PLC</td>
<td>9</td>
<td>64</td>
<td>2</td>
<td>13</td>
<td>14.35</td>
</tr>
<tr>
<td>J</td>
<td>PLC</td>
<td>9</td>
<td>94</td>
<td>2</td>
<td>40</td>
<td>14.10</td>
</tr>
<tr>
<td>K</td>
<td>PLC</td>
<td>10</td>
<td>89</td>
<td>7</td>
<td>5</td>
<td>11.10</td>
</tr>
<tr>
<td>L</td>
<td>VEN</td>
<td>9</td>
<td>85</td>
<td>4</td>
<td>48</td>
<td>11.40</td>
</tr>
<tr>
<td>M</td>
<td>VEN</td>
<td>9</td>
<td>67</td>
<td>8</td>
<td>15</td>
<td>11.90</td>
</tr>
<tr>
<td>N</td>
<td>VEN</td>
<td>10</td>
<td>107</td>
<td>1</td>
<td>4</td>
<td>12.00</td>
</tr>
<tr>
<td>O</td>
<td>VEN</td>
<td>12</td>
<td>67</td>
<td>5</td>
<td>34</td>
<td>15.05</td>
</tr>
<tr>
<td>P</td>
<td>VEN</td>
<td>13</td>
<td>65</td>
<td>1</td>
<td>8</td>
<td>12.00</td>
</tr>
<tr>
<td>Q</td>
<td>VEN</td>
<td>14</td>
<td>98</td>
<td>2</td>
<td>9</td>
<td>9.80</td>
</tr>
</tbody>
</table>

<sup>a</sup>Age (mean ± SE): FLX, 8 ± 0.5 y; PLC, 9 ± 0.5 y; and VEN, 11 ± 0.9 y

<sup>b</sup>Median no. of incidents of severe SIB: FLX, 3.5; PLC, 2.0; and VEN, 3.0

<sup>c</sup>No. of months (mean ± SE) since last incident of severe SIB: FLX, 22.2 ± 5.8; PLC, 15.8 ± 6.4; and VEN, 19.7 ± 7.1

---

**Figure 1.** Study design. A, steady-state trough plasma drug samples; B, blood samples for biochemical analyses; C, cerebrospinal fluid samples for neurochemical analyses.
with within-assay and assay-to-assay coefficients of time variation of 4% to 5%.

The 4-wk dose interval allowed sufficient time to reach steady-state drug levels, which usually are attained after 4 to 5 half-lives. In humans, the half-life for each compound is: FLX, 2 to 4 d; norfluoxetine, 7 to 15 d; and VEN, 11 h.6,25,43,47

Behavioral observations. Throughout the experiment, 10-min focal behavioral samples were collected from each animal twice weekly, including 1 morning and 1 afternoon sample. Animals were observed by trained technicians, who were blind to experimental condition, from a remote location by using a closed-circuit videocamera to eliminate interaction with observers. Behavioral data were collected by using handheld computers with The Observer software (Noldus Information Technology, Leesburg, VA). The Cohen kappa value for interobserver reliability was greater than 0.75.

Behaviors that occurred nearly instantaneously (lasting less than 5 s) were categorized as events and calculated as rates (that is, no. events/h). Behaviors that occurred over a period of time were categorized as states and calculated as rates and percentage of total observation time. All behavior was averaged over 2-wk time periods. We distinguished self-biting behavior that does not cause injury from self-wounding. Stereotypic behavior was categorized based on our previous work19 and modified from another previous study.40 General behaviors were those associated with normal activity (Figure 2).

Serum chemistries and physiologic measures. Hepatic and renal functions were monitored throughout the study by assessing hepatic enzymes (alanine aminotransferase, aspartate aminotransferase, gamma glutamyltransferase), triglycerides, albumin, creatinine, and blood urea nitrogen concentrations. These samples were collected at 4-wk intervals (Figure 1). Normal reference ranges for rhesus are well-established.5 Serum chemistries were processed by the Center’s clinical laboratory. At 4-wk intervals, animals were given a physical examination prior to CSF collection and anesthetized with ketamine HCl (15 mg/kg IM). Heart rate, blood pressure, body temperature, and body weight were obtained.

Neurochemical analyses. Cerebrospinal fluid was collected from the cisterna magna by using sterile technique. Animals were fasted for 12 h before sample collection. Samples were obtained within 20 min of anesthesia by using a 1.5-in. 25-gauge needle. Approximately 1.0 mL CSF was obtained from each animal and frozen at -70 °C until assayed for neurochemical concentrations. Blood samples were obtained at 4-week intervals for determination of platelet serotonin concentration (Figure 1).

Levels of platelet serotonin were determined by using reversed-phase HPLC and fluorometric or electrochemical detection as previously described.2,15 Compounds were determined with within-day and day-to-day coefficients of variation of 4.0% to 14%.

Statistical analyses. Because of poor compliance among animals treated with the highest dose level (DL4) of VEN, analyses of behavior, serum chemistry, and neurochemical data for animals treated with FLX, VEN, and PLC first were performed after excluding the highest dose level (DL4). Analyses of dose effects on behavior, serum chemistry, and neurochemical variables then were done for all dose levels in the FLX-treated and PLC animals. Analyses were done using Statistica (StatSoft, Inc, Tulsa, OK).

Total injuries for each animal were calculated for each treatment phase and analyzed by using repeated-measures ANOVA for animals in the VEN-treated condition through DL3 and for animals in the FLX-treated and PLC conditions through DL4.

Behavioral data were averaged over 2-wk time points to yield 2 baseline time points (B1, B2), 2 placebo time points (PP1, PP2), and 2 time points for each dose level (DL1-1, DL1-2, DL2-1, DL2-2, DL 3-1, DL 3-2). Mixed-model ANOVA (1 between- and 2 within-subjects factors) was used to assess the effects of the 3 dose levels of each drug on SIB, stereotypic and general behavior, serum chemistry, and neurochemical data. The between-subjects factor was drug condition (FLX-treated, VEN-treated, PLC), and the within-subjects factors were phase (B, PP, DL1, DL2, DL3) and time points (weeks 1 to 2, weeks 3 to 4) within each phase. All reported P values for effects involving within-subjects factors are Huynh–Feldt adjusted P values to correct for any possible violations of sphericity.26

Repeated-measures ANOVA was done to assess the effects of drug level on plasma drug (FLX and norfluoxetine) concentrations with phase (DL1 to DL4) as a within-subjects factor. Subsequent main effects and interactions were analyzed by using univariate contrasts. Correlations between CSF 5HIAA and platelet serotonin were computed separately for each subject in the FLX-treated and PLC conditions for the 6 phases (B through DL4) and for animals in the VEN-treated condition for weeks 2 through DL3. These correlations (FLX-treated, PLC: n = 6; VEN-treated: n = 5) were transformed to Fisher Z scores to meet normality assumptions and analyzed separately for each drug condition by using t tests. Mean Fisher Z scores were converted back to correlations for reporting. For animals in the FLX-treated condition, a similar analysis was used to assess the relationship between plasma drug concentrations, platelet serotonin, and CSF 5HIAA.

Results

Drug compliance (Table 2), as measured by the percentage of the offered drug that was consumed, was influenced by dose level and drug condition, as indicated by a phase × condition (FLX, VEN, or PLC) interaction (F3, 42 = 9.02; P < 0.001), a condition main effect (F1, 14 = 8.59; P < 0.01), and a phase main effect (F3, 42 = 22.16; P < 0.001). Among animals in the FLX-treated condition, compliance decreased significantly during DL3 as compared with DL1 (F1, 14 = 13.20; P < 0.01) and DL2 (F1, 14 = 15.23; P < 0.01). Compliance among animals in the FLX-treated condition increased significantly for DL4 compared with DL3 (F1, 14 = 7.19; P < 0.05) but remained significantly lower than DL1 (F1, 14 = 6.24, P < 0.05) and DL2 (F1, 14 = 4.96; P < 0.05). Among animals in the VEN-treated condition compliance declined significantly for the 2 highest dose levels. Compliance during DL3 was significantly lower than DL1 (F1, 14 = 18.85; P < 0.001) and DL2 (F1, 14 = 21.23; P < 0.001). Compliance in DL4 was significantly lower than for DL1 (F1, 14 = 70.47; P < 0.001), DL2 (F1, 14 = 74.98; P < 0.001), and DL3 (F1, 14 = 6.15; P < 0.05). Compliance among animals in the PLC condition was 100% throughout the study.

Among animals in the drug-treated conditions, compliance decreased significantly over time in the drug level as dose increased, as indicated by phase × time point × condition (F3, 42 = 4.25; P < 0.01) and phase × time point (F3, 42 = 6.67; P < 0.001) interactions and a time point main effect (F3, 42 = 9.59; P < 0.01). Animals in the FLX-treated condition were significantly less compliant during weeks 3 to 4 of DL3 (F1, 14 = 5.61; P < 0.05) compared with weeks 1 to 2 of DL3. For the 2 highest dose levels of the VEN-treated condition, compliance was significantly lower during weeks 3 to 4 compared with weeks 1 to 2 (DL3: F1, 14 = 15.42; P < 0.01; DL4: F1, 14 = 11.56; P < 0.01).
Fluoxetine and venlafaxine for SIB in macaques
time point as indicated by a phase × time point × condition interaction (F8, 56 = 3.50; P < 0.01), a phase × time interaction (F4, 56 = 4.37; P < 0.01), and a nearly significant phase × condition interaction (F8, 56 = 2.13; P = 0.066). For animals in the FLX-treated conditions, rates of self-biting increased significantly during weeks 1 to 2 of PP compared with B (F1, 14 = 11.83; P < 0.01) then declined significantly during weeks 3 to 4 of PP. In addition, among animals in the FLX-treated condition, rates of self-biting were significantly lower during DL1 (F1, 14 = 6.80; P < 0.05), DL2 (F1, 14 = 5.51; P < 0.05), and DL3 (F1, 14 = 6.67; P < 0.05) than they were in the averaged B and PP phases. Among animals in the FLX-treated condition, rates of self-biting did not differ significantly among DL1, DL2, and DL3. Rates of self-biting among animals in the FLX-treated condition during DL2 only were lower, approaching significance, compared with animals in the concomitant PLC condition (F1, 14 = 3.29; P = 0.09).

Self-biting did not decrease significantly among animals in the VEN-treated or PLC conditions. No incidence of self-wounding was observed directly during the study.

Self-biting state behavior, measured in percentage time, was affected by dose level and drug condition (Figure 5B; phase × time point × condition interaction: F8, 56 = 2.19, P < 0.05; phase main effect: F4, 56 = 2.74, P < 0.05). In the FLX-treated condition, percentage time self-biting increased significantly during PP compared with B (F1, 14 = 11.83; P < 0.01). Fluoxetine-treated animals spent significantly less percentage time self-biting during DL2 (F1, 14 = 6.71; P < 0.05) and DL3 (F1, 14 = 6.47; P < 0.05) compared with...
forming aggressive displays during DL2 (mean ± SE, 0.15% ± 0.05%; \( F_{1,14} = 4.62; P < 0.05 \)) and DL3 (0.07% ± 0.03%; \( F_{1,14} = 10.77; P < 0.01 \)) compared with the averaged B and PP phases (0.25% ± 0.07%).

In addition, a significant phase main effect (\( F_{4,56} = 3.99; P < 0.01 \)) was found for rates of yawning. Animals in all conditions yawned significantly less in DL1 (mean ± SE, 0.18% ± 0.02%; \( F_{1,14} = 5.41; P < 0.05 \)) and DL2 (0.18% ± 0.02%; \( F_{1,14} = 16.21; P < 0.001 \)) and DL3 (0.15% ± 0.02%; \( F_{1,14} = 5.41; P < 0.05 \)) compared with the averaged B and PP phases (0.25% ± 0.04%).

No significant main effects or interactions in percentage time scanning, resting, eating, investigating, or grooming nor in rates of scratching were found.

**Serum chemicals and physiologic measures.** No significant effects of drug condition or dose level on concentrations of hepatic enzymes (alanine aminotransferase, aspartate aminotransferase, gamma glutamyltransferase), triglycerides, albumin, creatinine, or blood urea nitrogen concentration were found.

A significant phase × condition interaction (\( F_{4,56} = 2.61; P < 0.05 \)) was found for heart rate. In the FLX-treated condition, heart rate decreased during DL3 (111 ± 5 beats per minute (bpm); \( F_{1,14} = 7.62; P < 0.05 \)) compared with the averaged B and PP phases. In DL3, heart rate among animals in the FLX-treated condition was significantly lower than in animals in the VEN-treated (130 ± 6 bpm; \( F_{1,14} = 5.37; P < 0.05 \)) and PLC (138 ± 7 bpm; \( F_{1,14} = 9.74; P < 0.01 \)) conditions. No significant effects of drug condition or dose levels on heart rate were found among animals in the VEN-treated and PLC conditions.

Neither drug condition nor dose levels affected blood pressure, body temperature, or body weight among animals in the FLX-treated, VEN-treated, or PLC conditions.

**Platelet serotonin.** Among animals in the FLX-treated and VEN-treated conditions, platelet serotonin concentrations decreased as dose levels increased (Figure 6 A; phase × condition interaction: \( F_{4,56} = 6.88; P < 0.01 \); condition main effect: \( F_{1,14} = 4.59; P < 0.05 \); phase main effect: \( F_{4,56} = 18.51; P < 0.001 \)).

Among animals in the FLX-treated condition, platelet serotonin concentrations decreased significantly during DL1 (\( F_{1,14} = 22.40; P < 0.01 \)), DL2 (\( F_{1,14} = 60.84; P < 0.001 \)), and DL3 (\( F_{1,14} = 31.21; P < 0.001 \)) compared with the averaged B and PP phases. In addition, among animals in the FLX-treated condition, platelet serotonin concentrations decreased significantly during DL2 (\( F_{1,14} = 56.72; P < 0.001 \)) and DL3 (\( F_{1,14} = 20.79; P < 0.001 \)) compared with DL1.

Among animals in the VEN-treated condition, platelet serotonin concentrations decreased significantly during DL1 (\( F_{1,14} = 44.91; P < 0.001 \)), DL2 (\( F_{1,14} = 16.10; P < 0.001 \)), and DL3 (\( F_{1,14} = 8.82; P < 0.001 \)) compared with the averaged B and PP phases.

During DL2 and DL3, platelet serotonin concentrations were significantly lower in the FLX-treated condition compared with the VEN-treated (DL1: \( F_{1,14} = 29.89; P < 0.01 \)), DL2 (\( F_{1,14} = 59.18; P < 0.001 \)), and PLC (DL2: \( F_{1,14} = 9.76; P < 0.01 \)) conditions.

No significant main effects or interactions in platelet serotonin concentrations between phases were found among animals in the PLC condition.

**Cerebrospinal fluid monoamines.** Cerebrospinal fluid 5HIAA concentrations were influenced by dose level and drug condition, as indicated by a significant phase × condition interaction (Figure 6 B; \( F_{4,56} = 2.90; P < 0.01 \)) and a phase main effect (\( F_{1,56} = 3.72; P < 0.01 \)). For animals in the FLX-treated condition, CSF 5HIAA was significantly lower during DL2 compared with the

### Table 2. Mean compliance (± SE) among animals in the FLX and VEN conditions

<table>
<thead>
<tr>
<th>Phase</th>
<th>FLX (mg/kg/24 h) % compliance</th>
<th>VEN (mg/kg/24 h) % compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td>DL1</td>
<td>0.5 100.0 (0)</td>
<td>2.0 96.8 (1.3)</td>
</tr>
<tr>
<td>DL2</td>
<td>2.0 96.1 (2.6)</td>
<td>4.0 96.8 (1.3)</td>
</tr>
<tr>
<td>DL3</td>
<td>4.0 61.3 (12.6)</td>
<td>8.0 50.5 (13.6)</td>
</tr>
<tr>
<td>DL4</td>
<td>8.0 80.8 (6.6)</td>
<td>16.0 32.4 (11.8)</td>
</tr>
</tbody>
</table>

**Figure 3.** Effects of dose level on concentrations (mean ± SE) of (A) plasma FLX and (B) plasma norfluoxetine among animals in the FLX-treated condition.

the averaged B and PP phases. Animals in the VEN-treated condition spent significantly less percentage time self-biting during DL2 compared with the averaged B and PP (\( F_{1,14} = 6.00; P < 0.05 \)) phases and DL1 (\( F_{1,14} = 7.93; P < 0.01 \)). There were no significant differences in percentage time self-biting among animals in the PLC condition.

There were no significant differences in phase or condition for percentage time spent performing self-directed stereotypies, stereotypic body movement, stereotypic posture, pacing, or environment-directed stereotypies.

**General behavior.** A significant phase main effect (\( F_{4,56} = 6.93; P < 0.001 \)) was found for percentage time locomoting. Animals in all conditions spent significantly less % time locomoting in DL1 (mean ± SE, 1.65% ± 0.34%; \( F_{1,14} = 5.41; P < 0.05 \)) and DL2 (1.44% ± 0.34%; \( F_{1,14} = 16.21; P < 0.001 \)) compared with the averaged B and PP phases. Percentage time spent locomoting in DL3 (1.09% ± 0.18%) was significantly lower than the averaged B and PP phases (2.17% ± 0.47%; \( F_{1,14} = 19.04; P < 0.001 \)), DL1 (\( F_{1,14} = 5.76; P < 0.05 \)), and DL2 (\( F_{1,14} = 5.12; P < 0.05 \)).

A significant phase main effect (\( F_{4,56} = 3.70; P < 0.05 \)) was found for percentage time spent performing aggressive displays. Animals in all conditions spent significantly less time per-
Effects of fluoxetine and placebo: DL4 comparisons. SIB and stereotypic behavior. In addition to the findings described previously, animals in the FLX-treated condition continued to exhibit decreased rates of self-biting and lower percentage time self-biting during DL4 (8 mg/kg) compared with the averaged B and PP phases (Table 3; $F_{1,9} = 6.38, P < 0.05$ and $F_{1,9} = 10.68, P < 0.01$, respectively). Rates of self-biting and percentage time self-biting in the PLC condition did not differ significantly between DL4 and the other phases. In addition, there were no significant differences for DL4 in self-directed stereotypies, stereotypic body movement, stereotypic posture, pacing, and environment-directed stereotypies.

General behavior. Percentage time spent locomoting remained significantly lower during DL4 (1.38% ± 0.32%; $F_{1,9} = 13.25; P < 0.001$) compared with the averaged B and PP phases (2.26% ± 0.52%).

No significant main effects or interactions in percentage time scanning, resting, eating, investigating, grooming or performing aggressive displays were found during DL4, nor were any significant differences found for rates of yawning and scratching.

Heart rate, blood pressure, temperature, and body weight. Heart rate (mean ± SE) remained lower among animals in the FLX-treated condition during DL4 (116 ± 7 bpm) compared with the averaged B and PP phases (127 ± 5 bpm; $F_{1,9} = 6.06, P < 0.05$). Animals in the PLC condition exhibited an increase in heart rate during DL4 (154 ± 6 bpm) compared with averaged B and PP phases (133 ± 7 bpm; $F_{1,9} = 14.39, P < 0.01$), DL2 (132 ± 7 bpm; $F_{1,9} = 13.60, P < 0.01$), and DL3 (138 ± 7 bpm; $F_{1,9} = 9.00, P < 0.01$). Heart rate was lower during DL4 among animals in the FLX-treated condition (116 ± 7 bpm) compared with animals in the PLC condition (154 ± 7 bpm; $F_{1,9} = 15.78, P < 0.01$).

Platelet serotonin. In addition to the reductions described previously, animals in the FLX-treated condition continued to exhibit decreased levels of platelet serotonin during DL4 compared with the averaged B and PP phases ($F_{1,9} = 105.6, P < 0.001$), DL1 ($F_{1,9} = 102.1, P < 0.001$), and DL2 ($F_{1,9} = 23.4, P < 0.001$; Table 3). Among animals in the PLC condition, platelet serotonin concentrations during DL4 did not differ from the previous phases. Platelet serotonin concentrations during DL4 were lower among animals in the FLX-treated condition compared with animals in the PLC condition ($F_{1,9} = 100.3, P < 0.001$).

Cerebrospinal fluid monoamines. Among animals in the FLX-treated condition, CSF 5HIAA concentrations during DL4 were significantly lower than those for the averaged B and PP phases (Table 3; $F_{1,9} = 20.6, P < 0.001$) and DL1 ($F_{1,9} = 16.5, P < 0.01$). In addition, CSF 5HIAA concentrations were significantly lower during DL4 among animals in the FLX-treated condition compared with animals in the PLC condition ($F_{1,9} = 6.8, P < 0.05$). No significant differences in CSF 5HIAA were found among animals in the PLC condition.

Relationships among plasma drug concentrations and neurochemical variables. Plasma FLX significantly positively correlated with plasma norfluoxetine ($r = 0.98, t_s = 18.7, P < 0.001$) and negatively correlated with platelet serotonin ($r = -0.75, t_s = -7.85, P < 0.001$) and CSF 5HIAA ($r = -0.52, t_s = -2.63, P < 0.05$). Plasma norfluoxetine concentrations were also significantly negatively correlated with platelet serotonin ($r = -0.82, t_s = -6.64, P < 0.001$) and CSF 5HIAA ($r = -0.53, t_s = -3.34, P < 0.05$).

Discussion

Fluoxetine treatment at doses of 0.5, 2.0, 4.0, and 8.0 mg/kg daily was efficacious in reducing rates of self-biting. A trend in reductions in new incidents of self-wounding was noted among...
to sedation. These results are consistent with previous research that demonstrated a significant reduction in rates of self-biting at 1 to 4 wk of treatment with 2.0 mg/kg FLX. However, the current study did not find significant effects of FLX on durations of self-directed stereotypic behavior. In the previous study, the effects on self-directed stereotypic behavior did not occur until 5 wk of treatment with 2.0 mg/kg daily. In addition, baseline levels of percentage time spent displaying self-directed stereotypic behavior in the current study were substantially lower than observed previously.

Compliance in the FLX-treated condition was generally high (100.0% to 96.1%) at the 0.5 and 2.0 mg/kg doses and decreased to 61.3% at 4.0 mg/kg and was 80.8% for the 8.0 mg/kg dose. Plasma concentrations of FLX and the active metabolite norfluoxetine increased with dose overall despite the reduced compliance at higher doses. Plasma FLX levels in animals receiving doses of 4.0 and 8.0 mg/kg daily approached those seen in human patients receiving a fixed dose of 20 mg daily for 8 wk and who were classified as responsive to treatment. However, plasma norfluoxetine levels in rhesus monkeys were at least 3-fold higher than typical human levels, as was the norfluoxetine:FLX ratio. Similar to the patient population, animals exhibited a large individual variability in plasma levels of FLX and norfluoxetine at all dose levels and showed no significant correlation between plasma drug or metabolite levels and reductions in self-biting.

Species differences in cytochrome P450 enzyme isoforms (for example, 2C, 2D, 3A) may contribute to variable metabolic profiles. As depicted in Figure 3, plasma FLX level showed an apparent nonlinear increase with dose, with increased dose leading to greater than proportional increases in levels. Although only trend-level significant (1-tailed \(P = 0.08\) ) when fit to a polynomial, this effect of FLX has been reported for humans and appears to result from FLX’s inhibition of cytochrome P450 enzymes.

Venlafaxine also reduced the percentage time spent self-biting at a dose of 4.0 mg/kg daily, with an average compliance of 91.6%. Percentage time spent self-biting at higher doses of VEN were not significantly different from averaged B and PP levels; however, compliance was significantly lower at the 2 highest dose levels (that is, 50.5% at 8.0 mg/kg daily and 32.4% at 16.0 mg/kg daily). Plasma VEN levels were not detectable (that is, less than 4 ng/mL) at all dose levels. VEN apparently is not only highly palatable to rhesus macaques but also is metabolized extremely rapidly.

Reductions in platelet serotonin, which result from inhibition of the platelet serotonin transporter, are thought to be closely related to the degree of peripheral and central blockade. In FLX-treated animals, plasma FLX and norfluoxetine levels correlated negatively with platelet serotonin and CSF 5HIAA. Platelet serotonin levels decreased significantly among animals in both the FLX-treated and VEN-treated conditions at all dose levels examined. However, platelet serotonin levels were significantly lower among animals in the FLX-treated condition compared with animals in the VEN-treated and PLC conditions. This result suggests that FLX treatment produced a greater blockade of serotonin transporter than did VEN.

Concentrations of 5HIAA in CSF were significantly decreased in animals treated with FLX at 2.0 and 8.0 mg/kg daily. Problems with compliance among animals treated with 4.0 mg/kg daily of FLX may have influenced the apparent lack of response during this phase. Previous studies reported a 42% to 50% reduction in CSF 5HIAA after chronic SSRI administration to monkeys and is consistent with the 40% to 60% declines seen in human patients receiving a fixed dose of 20 mg daily.
typically seen in human lumbar CSF after sustained clinical SSRI treatment.48 The SSRI-induced reduction in human CSF 5HIAA is well established and has been presumed to be due to uptake blockade leading to increased extracellular serotonin, resulting in a compensatory terminal autoreceptor-mediated decrease in serotonin turnover.2 As expected given the proposed mechanisms for the reductions seen in platelet serotonin and CSF 5HIAA, the 2 measures were highly correlated in the FLX-treated animals.

Given the absence of effects on CSF 5HIAA and the minimal effects on platelet serotonin, VEN appeared to have little effect on peripheral or central serotonin transport at the doses examined. Therefore, other mechanisms, such as noradrenergic reuptake inhibition, may be responsible for the decreases in percentage time spent self-biting found among animals treated with 4 mg/kg VEN (DL2). Venlafaxine has shown efficacy for treatment of SIB and repetitive behavior in patients with developmental disorders.7,24 Further studies will be required to fully address the potential efficacy of VEN or other SNRIs on self-injurious behavior in macaques.

In conclusion, given the relatively high rate of compliance and significant decreases in rates and percentage time spent self-biting, FLX at a dose of 2.0 mg/kg daily demonstrated the most efficacy. The reductions in platelet serotonin and CSF 5HIAA levels at this dose reflect substantial decreases in serotonin reuptake (bioeffect). At this dosage, no adverse effects on hepatic or renal indices or on physiologic variables (that is, heart rate, blood pressure, and body weight) were noted. Long-term studies are required to provide a more comprehensive characterization of the utility and effectiveness of FLX in the prevention and treatment of SIB in macaques. Although the SNRI VEN appeared less promising, other, less-aversive SNRIs might prove to be useful. Such studies likely will improve the care of captive macaques and may lead to useful models of human self-injurious behavior.

Acknowledgments

We thank Dr Thomas J Rowell for administrative support. We appreciate the technical assistance of Amy Dupuy, Amber Wright, and Michelle Grisham. We thank Charlie Perioux and his staff from the Division of Animal Resources for their care of the animals. This research was supported in part from a 2005 grant from the ACLAM Foundation.

References

27. International Veterinary Information Service [Internet]. Evaluation and management of behavioral conditions [cited 18 Feb


